Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999968 | 0.82 | SELE (0.51) | MEN1KMT2A | |
| SCHEMBL21427134 | 0.79 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL21427131 | 0.79 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL22926960 | 0.78 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL3995602 | 0.76 | ADORA1 (0.45) | — | |
| SCHEMBL4947940 | 0.76 | CSNK1A1 (0.36) | — | |
| SCHEMBL22926964 | 0.76 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL22926974 | 0.75 | MEN1 (0.53) | MEN1KMT2A | |
| SCHEMBL3993667 | 0.74 | CSNK1A1 (0.34) | — | |
| SCHEMBL3992555 | 0.74 | CSNK1A1 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3835304-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-16 | — | — | EP | disclosed |
| EP-3835304-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-20210024547-A1 | OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20210024547-A1 | OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
| WO-2020032105-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | 大日本住友製薬株式会社 | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024547-A1 | OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE | MLLT3, MEN1, MLLT1 | MEN1 2/4885KMT2A 32/4885 |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | MLLT3, MLLT1, MEN1 | MEN1 3/4885KMT2A 92/4885 |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | MLLT3, MEN1, MLLT1 | MEN1 2/4885KMT2A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.